^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    OCV-501

    i
    Other names: OCV-501, OCV501, Wilms tumor 1 (WT1) targeted cancer vaccine
    Associations

    News

    Trials
    Company:
    Otsuka
    Drug class:
    Immunostimulant, Wilms tumor 1 antigen modulator
    Related drugs:
    Associations

    News

    Trials
    over1year
    Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide. (PubMed, Cancer Immunol Immunother)
    Anti-OCV-501 IFNγ responses were less frequent than the IgG reactions. These findings suggest that host immunoreactivity has a significant impact on the prognosis of AML and that further improvement of the WT1 peptide vaccine is needed.
    P2 data • Journal
    |
    IFNG (Interferon, gamma) • WT1 (WT1 Transcription Factor)
    |
    OCV-501
    3years
    Efficacy and safety of Wilms' tumor 1 helper peptide OCV-501 in elderly patients with acute myeloid leukemia: a multicenter, randomized, double-blind, placebo-controlled phase 2 trial. (PubMed, Cancer Immunol Immunother)
    The placebo-controlled design of this study and quantitative immunological monitoring provides new insight into the relationship between peptide-induced immune responses and survival, suggesting future perspectives for cancer immunotherapy.
    Clinical • P2 data • Journal
    |
    IFNG (Interferon, gamma) • WT1 (WT1 Transcription Factor)
    |
    OCV-501